Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

NOT YET RECRUITING

Identifier: CI-TRIAL-00113975
Entity page: /trial/NCT07332351 ↗
Edges: 7

Neighbours: 2 cancers4 drugs
Drawn: 6 of 6 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial condition of …CONDITION_OFderived3 of 3
← condition of	Malignant Bladder Neoplasm registry condition “Stage II Bladder Cancer AJCC v8” mapped CURATED_BROADER	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Malignant Bladder Neoplasm registry condition “Stage IIIA Bladder Cancer AJCC v8” mapped CURATED_BROADER

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial intervention of …INTERVENTION_OFderived4 of 4
← intervention of	Cisplatinsmall molecule registry intervention “Cisplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Durvalumabmonoclonal antibody registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Nadofaragene Firadenovecgene therapy registry intervention “Nadofaragene Firadenovec” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial intervention of …INTERVENTION_OFderived4 of 4

← intervention of

Cisplatinsmall molecule

registry intervention “Cisplatin” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Durvalumabmonoclonal antibody

registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS

—